Search the Newsreel

Danaher Posts Mixed Q2 Results, Outlook for 2027 and Beyond Strengthened, RBC Says

Danaher's (DHR) Q2 results were mixed, with the lumpier part of its bioprocess consumables business PREMIUM Upgrade to read this MT Newswires article and get so much more. A Silver or Gold subscription plan is required to access premium news articles. Upgrade Already have …

Can Danaher (DHR) Climb 32.39% to Reach the Level Wall Street Analysts Expect?

Danaher (DHR) closed the last trading session at $179.01, gaining 0% over the past four weeks, but there could be plenty of upside left in the stock if short-term price targets set by Wall Street analysts are any guide. The mean price target of …

Don’t Quit on Danaher Stock After Horrific Earnings Reaction

To say Danaher Corp. had a downbeat reaction to earnings is an understatement. Danaher had its worst day in two decades on Tuesday after the life sciences and diagnostics company’s second-quarter earnings. Danaher expects core revenue (a metric that excludes things like currency and …

Adaptive Biotechnologies (ADPT) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release

Adaptive Biotechnologies (ADPT) is expected to report a year-over-year increase in earnings on higher revenues for the quarter ended June 2026, with an anticipated loss of $0.13 per share. The company currently holds a Zacks Rank #2, but its Earnings ESP of 0% suggests …

Danaher’s Q2 Earnings Call Shows Life Sciences at Its Best Quarter in Years

AdaptHealth Corp. (AHCO) Stock Analysis: Exploring a 24% Potential Upside in the Healthcare Sector

AdaptHealth Corp. (AHCO), a U.S.-based medical equipment distributor with a market cap of $1.49 billion, shows a potential upside of 24.09% according to analyst consensus, despite current profitability challenges. While the company faces a negative EPS and ROE, its robust free cash flow of …

Danaher (DHR) Q2 2026 Earnings Call Transcript

Image source: The Motley Fool. DATE Tuesday, July 21, 2026 at 8 a.m. ET CALL PARTICIPANTS Vice President of Investor Relations - Rachel VatnsdalPresident and Chief Executive Officer - Rainer BlairExecutive Vice President and Chief Financial Officer - Matt Gugino TAKEAWAYS Revenue -- $6.3 …

ADPT (ADPT) Form 144 shows Harlan Robins planning sizable stock sale

Harlan Robins, an insider at Adaptive Biotechnologies Corp (ADPT), has filed a Form 144 indicating a planned sale of common stock through Goldman Sachs & Co. LLC, with an anticipated transaction date of July 21, 2026. The filing details securities information including figures of …

Why Danaher (DHR) Shares Are Falling Today

Why Danaher (DHR) Shares Are Falling Today What Happened? Shares of diversified science and technology company Danaher (NYSE:DHR) fell 13.3% in the morning session after it reported underwhelming second-quarter results. The negative reaction appeared to stem from underlying concerns about the company's profitability. While …

Cardinal Health makes acquisition duo worth $360m for home care business advance

US drug and medical supplies distributor Cardinal Health has simultaneously acquired urology-focused medical supplier Strive Medical and AdaptHealth's diabetes business in a deal duo totalling $360m that is positioned to advance its home care business service provision. Regarding diabetes, the buyout of AdaptHealth's business …

Danaher forecasts 3%-4% 2026 core revenue growth and raises adjusted EPS to $8.45-$8.60 following Masimo close

Earnings Call Insights: Danaher (DHR) Q2 2026 MANAGEMENT VIEW * "We delivered a solid second quarter with better-than-expected revenue, earnings and cash flow" (President, CEO & Director Rainer Blair), adding, "Our Life Sciences businesses delivered their strongest quarter in several years" and "the earlier-than-expected …

Adaptive Biotechnologies (ADPT) Upgraded to Buy: What Does It Mean for the Stock?

Adaptive Biotechnologies (ADPT) could be a solid addition to your portfolio given its recent upgrade to a Zacks Rank #2 (Buy). This upgrade primarily reflects an upward trend in earnings estimates, which is one of the most powerful forces impacting stock prices. The sole …

Danaher Plummets After One Segment Comes In 'Surprisingly Soft'

Danaher stock plummeted Tuesday after reporting what one analyst called "surprisingly soft" bioprocessing sales. Continue Reading

Behind Danaher’s Worst Stock Selloff in Over 30 Years

Danaher posts better-than-expected earnings, but its core revenue forecast disappoints and send shares tumbling. Continue Reading

Danaher Q2 Earnings Call Highlights

Key Points Interested in Danaher Corporation? Here are five stocks we like better. Danaher beat Q2 expectations with sales of $6.3 billion, adjusted EPS of $1.94, and $1.3 billion in free cash flow. Core revenue rose 3% year over year, with management saying performance …

Compared to Estimates, Danaher (DHR) Q2 Earnings: A Look at Key Metrics

For the quarter ended June 2026, Danaher (DHR) reported revenue of $6.27 billion, up 5.5% over the same period last year. EPS came in at $1.94, compared to $1.80 in the year-ago quarter. The reported revenue represents a surprise of +2.88% over the Zacks …

Danaher (DHR) Q2 Earnings and Revenues Top Estimates

Danaher (DHR) came out with quarterly earnings of $1.94 per share, beating the Zacks Consensus Estimate of $1.84 per share. This compares to earnings of $1.8 per share a year ago. These figures are adjusted for non-recurring items. This quarterly report represents an earnings …

Danaher shares tumble despite earnings beat

Investing.com -- Danaher Corporation (NYSE:DHR) reported second quarter results that exceeded analyst expectations, but shares fell 9% premarket. The company posted adjusted earnings per share of $1.94, beating the analyst consensus of $1.84 by $0.10. Revenue reached $6.3 billion, surpassing the $6.1 billion estimate …

Danaher (NYSE:DHR) Posts Better-Than-Expected Sales In Q2 CY2026 But Stock Drops

Danaher (NYSE:DHR) Posts Better-Than-Expected Sales In Q2 CY2026 But Stock Drops Diversified science and technology company Danaher (NYSE:DHR) reported Q2 CY2026 results exceeding the market's revenue expectations , with sales up 5.5% year on year to $6.27 billion. Its non-GAAP profit of $1.94 per …

Danaher Reports Second Quarter 2026 Results

WASHINGTON, July 21, 2026 /PRNewswire/ -- Danaher Corporation (NYSE: DHR) today announced results for the second quarter 2026. All results in this release reflect only continuing operations and period-to-period comparisons are year-over-year unless otherwise noted. Key Second Quarter 2026 Results Net earnings were $870 …

Adaptive Biotechnologies Corp (ADPT) Stock Analysis: Revenue Growth Amidst Valuation Challenges

Adaptive Biotechnologies Corp (ADPT) shows significant revenue growth of 35.10% driven by its immune medicine platform and clonoSEQ diagnostic test, yet faces profitability challenges with a negative EPS and ROE. Despite current unprofitability, investor sentiment is largely optimistic, with analysts setting a price target …

Danaher-Aktie fällt nach Masimo-Schluss trotz angehobener Prognose: Wa

AdaptHealth Divests Diabetes Health Unit To Cardinal Health In $235 Mln Deal

(RTTNews) - AdaptHealth Corp. (AHCO) announced that it is divesting its Diabetes Health business to Cardinal Health, Inc. (CAH). Cardinal Health will acquire AdaptHealth's Diabetes Health business for $235 million in cash, subject to customary purchase price adjustments. AdaptHealth provides healthcare-at-home solutions including home …

Cardinal Health To Buy AdaptHealth's Diabetes Unit, Strive Medical For $360 Mln Total

(RTTNews) - Healthcare services company Cardinal Health, Inc. (CAH) announced late Monday its agreement to acquire the Diabetes Health business of AdaptHealth Corp. (AHCO), as well as Strive Medical, a multi-specialty supply provider with a focus on urology. The combined price for the transactions …

Adaptive Biotechnologies (NASDAQ: ADPT) CCO sells 5,000 shares in plan

Susan Bobulsky, Chief Commercial Officer of Adaptive Biotechnologies Corp (NASDAQ: ADPT), sold 5,000 shares of common stock on July 16, 2026, at a price of $23.00 per share. This transaction was conducted under a Rule 10b5-1 trading plan adopted on December 16, 2025. Following …

AdaptHealth (AHCO) to Sell Diabetes Health Business for $235M

AdaptHealth (AHCO) announced its decision to sell its Diabetes Health division to Cardinal Health for $235 million. This strategic divestiture aims to allow AdaptHealth to concentrate on its core operations in sleep, respiratory, and home medical equipment, strengthen its financial position, and reinvest in …

AdaptHealth Corp. Enters into Definitive Agreement to Divest Diabetes Health Business to Cardinal Health

Continues the Company's multi-year effort to focus its portfolio on its core sleep, respiratory, and supporting home medical equipment businesses Sharpens strategic focus on businesses where the Company crosses the threshold of the home to deliver clinical value to patients Increases capital flexibility for …

Danaher (DHR) Q2 Earnings Report Preview: What To Look For

Danaher (DHR) Q2 Earnings Report Preview: What To Look For Diversified science and technology company Danaher (NYSE:DHR) will be reporting results this Tuesday before market hours. Here's what you need to know. Danaher missed analysts' revenue expectations last quarter, reporting revenues of $5.95 billion, …

Signal Proxy Intelligence Recommends Full Support for All Three Items at Indaptus Therapeutics, Inc. Annual Meeting

Signal Proxy Intelligence has published its recommendations for the Indaptus Therapeutics, Inc. annual meeting on August 10, 2026, advising full support for all three ballot items. The firm recommends "FOR" on the advisory vote on executive compensation, "FOR" on the election of directors, and …

Danaher Aktie: EPS erwartet bei 1,84 Dollar

Adaptive Biotechnologies CPO Lo reports $2.39m stock sale

Adaptive Biotechnologies' Chief People Officer, Francis Lo, sold approximately $2.39 million worth of company stock on July 15, 2026, executed under a Rule 10b5-1 trading plan. This transaction involved selling 105,762 shares at a weighted average price of $22.59, while simultaneously acquiring the same …

Adaptive Biotechnologies Corp (ADPT) officer exercises 105,762 options and sells 105,762 shares

Adaptive Biotechnologies Corp's Chief People Officer, Francis Lo, exercised 105,762 stock options with various strike prices and subsequently sold all 105,762 common shares at a weighted average price of $22.59 on July 15, 2026. These transactions, conducted under a Rule 10b5-1 trading plan adopted …

Form 4 Adaptive Biotechnologies Corp For: 17 July By Investing.com

This article reports on a Form 4 filing for Adaptive Biotechnologies Corp on July 17. Form 4s are filed with the SEC whenever there is a material change in the holdings of company insiders. The content is very brief, stating only the company and …

Behavioral Patterns of AHCO and Institutional Flows

This article provides an in-depth analysis of Adapthealth Corp. (NASDAQ: AHCO) based on AI-generated signals and institutional trading strategies. It highlights strong sentiment supporting an overweight bias, outlines specific entry and exit points for long and short positions, and details support and resistance levels …

Planned 5,000-share stock sale for ADPT (NASDAQ: ADPT)

Susan Bobulsky plans to sell 5,000 shares of Adaptive Biotechnologies Corp (ADPT) common stock, valued at $114,500, with a planned sale date of July 16, 2026. The shares originate from previously exercised stock options and will be sold through Morgan Stanley Smith Barney LLC …

Indaptus Therapeutics (INDP) Proxy filing Summary

Indaptus Therapeutics (INDP) has scheduled its Annual Meeting for August 10, 2026, to be held virtually. Key proposals include the election of Class II directors, ratification of Haskell & White LLP as independent auditor, and approval of a new equity incentive plan, all recommended …